LeanLegal™

Imagine rapid-response legal services, unfettered by conflicts and bandwidth constraints. Fold in lower-cost, bespoke quality, high-throughput work product. This is LeanLegal.

Disruptive innovation for legal services and products is well underway, worldwide. Immersed in this phase transition, David designed a model to solve for the intractable structural issues of the big law firm by leveraging the accumulated depth and breadth of his knowledge, experience and network.

David began his career in the courtroom, leading dozens of civil trials; jury and bench, state and federal. He has briefed and argued numerous state appellate matters, with 6 opinions issued, including a Florida Supreme Court argument demonstrating the prima facie unconstitutionality of a sales tax on commercial speech, and an Alaska Supreme Court argument that re-wrote a statutory healthcare payment formula.

In Silicon Valley, he has litigated scores of patent, copyright, trade secret and business cases, and managed hundreds of transactional and corporate governance issues. First with Fenwick & West, thereafter Morgan, Lewis & Bockius, he represented an array of technology and business clients, including Apple, Brøderbund, Cisco, Electronic Arts, Intuit, McKesson, Merrill-Lynch, Sankyo Pharma, Symantec, Tibco, and The Computer History Museum, pro bono.

David’s first General Counsel role in Silicon Valley was with Internet pioneer AllAdvantage.com, blending online advertising with early-stage social media and user-data mining. A CSFB company valued at $1.6b for IPO, AADV ultimately fell victim to the crash of 2000. Thereafter, he took the reins as GC and COO for turnaround of a boutique Palo Alto innovation incubator, for which he negotiated a joint-venture-to-acquisition with Vanderbilt University Medical Center, resulting in the nation’s first Healthcare Strategy & Innovation Center.

Remaining in the valley, David moved next into biotech as Deputy General Counsel for Xenogen (NYSE: XGEN), which coupled genetic engineering and in vivo biophotonics inventions by Stanford Professor Chris Contag to create novel breakthroughs for cancer research. David co-managed Xenogen’s public-public merger with Caliper Life Sciences (NASD: CALP), a global microfluidics and lab instrumentation developer, after which he was brought over as Caliper’s DGC. Several years thereafter, David moved next to healthcare when he was recruited by former client Triage Consulting Group to become both a Principal and General Counsel for this privately-held revenue-cycle consultancy for academic, children’s and community hospitals nationwide. After five years there, he began the design and implementation of a customized legal and business solution for a select set of clients.